CONTRACEPTIVE UPDATE
World's first non-hormonal contraceptive
The world's first non-hormonal
contraceptive pill Centchroman,
developed by a team of Indian
scientists,
promises
risk-free
contraception.
The pill was developed at the
Central Drug Research Insti tute (CDRI)
after over two decades of research and
trials.
The scientists say Centchroman
has none of the side-effects associated
with the use of the hormonal pill, like
vomiting, nausea, dizziness or other
systemic effects such as weight gain
and thrombotic episodes. The pill has
no effect on pituitary or thyroid
function or that of the ovaries,
hypothalamus or sperm.
The contraceptive effect of this pill
is due to the action of a weak oestrogen
and a potent anti-oestrogen, that
changes the nature of the uterus, thus
preventing a fertilized egg from
implanting on it. It is unique in being
a post-coital agent.
Dr Nityanand, a member of the
CDRI team, points out that this is the
only non-steroidal contraceptive that
has been granted permission for release
by the Drugs Controller of India.
One million pills have been
manufactured by the Ahmedabad
based company Torrent Pharma-
ceuticals Ltd and as sales are high, the
company is confident about stepping
up production.
Hindustan Latex, India's largest
manufacturer of condoms, markets
Centchroman under the brand name
Saheli 'in the northern region. It plans
to increase its production to about two
million pills every month and promote
its marketing using broad-based multi-
media advertising.
Launched in July 1991, Saheli has
been approved for inclusion in the
national family welfare programme.
Family Welfare MihistrySecretary,
Usha Vohra says government had
decided to distribute it through its
social marketing network in four north
Indian states where fertility rates are
high.
Injectable Contraceptive
likely.soon
Indian women may soon get
another choice of a contraceptive. If all
goes well, the American injection,
Depo Provera, to be taken once every
three months, could be marketed in
the country.
The Union Health and Family
Welfare Ministry, it is learnt, has
recently approved the private
marketing
of the injectable
contraceptive. This follows the
recommendation made by the technical
Parivar Seva Sanstha has started a
phone-in counselling service in
Delhi on family planning methods,
adolescence problems, STDs,AIDS,
Drugs, etc. Service is available on
phone no. 4611819 between 7 A.M.
and 7 P.M. seven days a week.
committee of the Directorate General
of Health Services (DGHS) on
contraceptives.
So far as incorporation of the
intra-muscular
injection in the
government's family programme is
concerned, the ministry has not yet
taken any decision.
The proposal to add Depo Provera
in the contraceptive basket was mooted
early last year. But it met with
resistance from a number of women
groups, on the grounds that is has not
even been approved in the country of
its origin. According to Ministry
sources this hurdle can now be
overcome as the Federal Drug
Authority (FDA) in the U.S. had cleared
(around October last year) the
contraceptive.
The private marketing of the "once
in three months shot", however, will
all depend on a tie-up between an
Indian drug company with the
American firm, UpjohnCo.
for
procurement of the basic raw material.
This should not pose any difficulty in
view of the recent import policy
liberalisation.
Anti-fertility vaccine enters
second phase of trials
The anti-fertility
vaccine
developed by Dr. G.P. Talwar's team
at the National Institute of
Immunology (NIl), New Delhi has
entered the second phase of human
clinical trials after establishing its safety
and effectiveness in the first phase. It
promises to be a potent tool in the
population control programme.
Out of 1,042 menstrual cycles
observed, pregnancy was reported only
in one case. The women volunteers
were immunised with the vaccine at
three centres-the All India Institute
of Medical Sciences and Safdarjung
Hospital, both in the Capital and the
Post Graduate Institute of Medical
Education and Research, Chandigarh.
According to the norms of
international
committee
for
contraception research, New York,
recording of 750 protected menstrual
cycles is mandatory before declaringa
vaccine as effective. NIl trials achieved
this target last April. This is the first
known birth control vaccine to reach
this stage of trial in the world.
According to the annual report
(1992-93) of. the Department of
Biotechnology, which sponsored the
vaccine research programme, the
vaccine has successfully completed
the first phase of human clinical trials
and proved to be safe. The second
phase of the trials was to go on till June
end and the next phase is likely to start
in 1994.
A similar anti-fertility vaccine for
men, developed at the Indian Insti tute
of Science, Bangalore, will also enter
the phase-I human clinical trials this
year. The vaccine has been tested in
sub-human primates such as monkeys.
Published by the FAMILY PLANNING FOUNDATION, 8-28, Qutab Institutional Area, New Delhi-11OO16. Tel.: 668181, 6867080, 6867081.
Designed and Printed by Reproductions India, Kapoor Holiday Inn, F-39, East of Kailash, New Delhi-110064. Tel. 6422289, 6415600.
Editorial Direction and Guidance: Harish Khanna
Editorial Consultant: J.L. Saaz